235 related articles for article (PubMed ID: 14664904)
1. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Lentz SR; Rodionov RN; Dayal S
Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
[TBL] [Abstract][Full Text] [Related]
2. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
3. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
Böger RH; Vallance P; Cooke JP
Atheroscler Suppl; 2003 Dec; 4(4):1-3. PubMed ID: 14664896
[No Abstract] [Full Text] [Related]
5. ADMA and oxidative stress.
Sydow K; Münzel T
Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
8. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
Magné J; Huneau JF; Borderie D; Mathé V; Bos C; Mariotti F
Amino Acids; 2015 Sep; 47(9):1975-82. PubMed ID: 25792109
[TBL] [Abstract][Full Text] [Related]
9. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
Böger RH; Zoccali C
Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
[TBL] [Abstract][Full Text] [Related]
11. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
13. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
15. [Methylarginies-induced endothelial dysfunction in chronic kidney disease].
Kimura K
Yakugaku Zasshi; 2012; 132(4):443-8. PubMed ID: 22465920
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency.
Rocha MS; Teerlink T; Janssen MC; Kluijtmans LA; Smulders Y; Jakobs C; Tavares de Almeida I; Rivera I; Castro R; Blom HJ
Atherosclerosis; 2012 Jun; 222(2):509-11. PubMed ID: 22484094
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
Stühlinger MC; Tsao PS; Her JH; Kimoto M; Balint RF; Cooke JP
Circulation; 2001 Nov; 104(21):2569-75. PubMed ID: 11714652
[TBL] [Abstract][Full Text] [Related]
19. Endothelial cell dysfunction: the syndrome in making.
O'Riordan E; Chen J; Brodsky SV; Smirnova I; Li H; Goligorsky MS
Kidney Int; 2005 May; 67(5):1654-8. PubMed ID: 15840005
[TBL] [Abstract][Full Text] [Related]
20. [Asymmetric dimethyl arginine (ADMA): a novel cardiovascular risk factor?].
Stühlinger M
Wien Med Wochenschr; 2007 Feb; 157(3-4):57-60. PubMed ID: 17340060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
